|
1
|
Vu M, Yu J, Awolude OA and Chuang L:
Cervical cancer worldwide. Curr Probl Cancer. 42:457–465. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cohen PA, Jhingran A, Oaknin A and Denny
L: Cervical cancer. Lancet. 393:169–182. 2019. View Article : Google Scholar
|
|
3
|
Lei J, Ploner A, Elfstrom KM, Wang J, Roth
A, Fang F, Sundström K, Dillner J and Sparén P: HPV vaccination and
the risk of invasive cervical cancer. N Engl J Med. 383:1340–1348.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sawaya GF, Smith-McCune K and Kuppermann
M: Cervical cancer screening: More choices in 2019. JAMA.
321:2018–2019. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnson CA, James D, Marzan A and Armaos
M: Cervical cancer: An overview of pathophysiology and management.
Semin Oncol Nurs. 35:166–174. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scarth JA, Patterson MR, Morgan EL and
Macdonald A: The human papillomavirus oncoproteins: A review of the
host pathways targeted on the road to transformation. J Gen Virol.
102:0015402021. View Article : Google Scholar
|
|
7
|
Koh WJ, Abu-Rustum NR, Bean S, Bradley K,
Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, et al: Cervical
cancer, version 3.2019, NCCN clinical practice guidelines in
oncology. J Natl Compr Canc Netw. 17:64–84. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marth C, Landoni F, Mahner S, McCormack M,
Gonzalez-Martin A and Colombo N; ESMO Guidelines Committee, :
Cervical cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 28:iv72–iv83. 2017. View Article : Google Scholar
|
|
9
|
Eleutherakis-Papaiakovou V, Bamias A and
Dimopoulos MA: Thalidomide in cancer medicine. Ann Oncol.
15:1151–1160. 2004. View Article : Google Scholar
|
|
10
|
Tamalunas A, Sauckel C, Ciotkowska A, Rutz
B, Wang R, Huang R, Li B, Stief CG, Gratzke C, Hennenberg M, et al:
Inhibition of human prostate stromal cell growth and smooth muscle
contraction by thalidomide: A novel remedy in LUTS? Prostate.
81:377–389. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu J, Yang Y, Liu S, Xu H, Wu Y, Zhang G,
Wang Y, Wang Y, Liu Y and Guo Q: Anticancer effect of thalidomide
in vitro on human osteosarcoma cells. Oncol Rep. 36:3545–3551.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang Y, Zhu YQ, Jiang L, Li LF and Ge JP:
Thalidomide induces apoptosis in human oral squamous cell carcinoma
cell line with altered expression of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL). Oral Oncol. 47:927–928. 2011.
View Article : Google Scholar
|
|
13
|
Vasvari GP, Dyckhoff G, Kashfi F, Lemke B,
Lohr J, Helmke BH, Schirrmacher V, Plinkert PK, Beckhove P,
Herold-Mende CC, et al: Combination of thalidomide and cisplatin in
an head and neck squamous cell carcinomas model results in an
enhanced antiangiogenic activity in vitro and in vivo. Int J
Cancer. 121:1697–1704. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Murphy S, Davey RA, Gu XQ, Haywood MC,
McCann LA, Mather LE and Boyle FM: Enhancement of cisplatin
efficacy by thalidomide in a 9L rat gliosarcoma model. J
Neurooncol. 85:181–189. 2007. View Article : Google Scholar
|
|
15
|
Shen Y, Li S, Wang X, Wang M, Tian Q and
Yang J, Wang J, Wang B, Liu P and Yang J: Tumor vasculature
remolding by thalidomide increases delivery and efficacy of
cisplatin. J Exp Clin Cancer Res. 38:4272019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Yu J, Wang J, Ni X, Sun Z, Sun W,
Sun S and Lu Y: Thalidomide combined with chemo-radiotherapy for
treating esophageal cancer: A randomized controlled study. Oncol
Lett. 18:804–813. 2019.
|
|
17
|
Khezri MR, Jafari R, Yousefi K and
Zolbanin NM: The PI3K/AKT signaling pathway in cancer: Molecular
mechanisms and possible therapeutic interventions. Exp Mol Pathol.
127:1047872022. View Article : Google Scholar
|
|
18
|
Jin W: Role of JAK/STAT3 signaling in the
regulation of metastasis, the transition of cancer stem cells, and
chemoresistance of cancer by epithelial-mesenchymal transition.
Cells. 9:2172020. View Article : Google Scholar
|
|
19
|
Zheng X, Zhu Y, Wang X, Hou Y and Fang Y:
Silencing of ITGB6 inhibits the progression of cervical carcinoma
via regulating JAK/STAT3 signaling pathway. Ann Transl Med.
9:8032021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang L, Wu J, Ling MT, Zhao L and Zhao
KN: The role of the PI3K/Akt/mTOR signalling pathway in human
cancers induced by infection with human papillomaviruses. Mol
Cancer. 14:872015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kian MM, Salemi M, Bahadoran M, Haghi A,
Dashti N, Mohammadi S, Rostami S, Chahardouli B, Babakhani D and
Nikbakht M: Curcumin combined with thalidomide reduces expression
of STAT3 and Bcl-xL, leading to apoptosis in acute myeloid leukemia
cell lines. Drug Des Devel Ther. 14:185–194. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun X, Xu Y, Wang Y, Chen Q, Liu L and Bao
Y: Synergistic inhibition of thalidomide and icotinib on human
non-small cell lung carcinomas through ERK and AKT signaling. Med
Sci Monit. 24:3193–3203. 2018. View Article : Google Scholar
|
|
23
|
Lee JH, Chung KS, Lee HH, Ko D, Kang M,
Yoo H, Ahn J, Lee JY and Lee KT: Improved tumor-suppressive effect
of OZ-001 combined with cisplatin mediated by mTOR/p70S6K and STAT3
inactivation in A549 human lung cancer cells. Biomed Pharmacother.
142:1119612021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Y, Yang Z, Zhang R, Jia C, Mao R,
Mahati S, Zhang Y, Wu G, Sun YN, Jia XY, et al: MiR-27a-3p enhances
the cisplatin sensitivity in hepatocellular carcinoma cells through
inhibiting PI3K/Akt pathway. Biosci Rep. 41:BSR201920072021.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu F, Li Q, Wang Z and Cao X: Sinomenine
inhibits proliferation, migration, invasion and promotes apoptosis
of prostate cancer cells by regulation of miR-23a. Biomed
Pharmacother. 112:1085922019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L,
Shen Y, Liu YY, Chen C, Cheng Y, Xu L, et al: Gefitinib versus
vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA
(N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): A randomised,
open-label, phase 3 study. Lancet Oncol. 19:139–148. 2018.
View Article : Google Scholar
|
|
28
|
Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu
CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani
AB, et al: Bladder preservation with twice-a-day radiation plus
fluorouracil/cisplatin or once daily radiation plus gemcitabine for
muscle-invasive bladder cancer: NRG/RTOG 0712-a randomized phase II
trial. J Clin Oncol. 37:44–51. 2019. View Article : Google Scholar
|
|
29
|
Kitagawa R, Katsumata N, Shibata T, Kamura
T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M,
Satoh T and Yoshikawa H: Paclitaxel plus carboplatin versus
paclitaxel plus cisplatin in metastatic or recurrent cervical
cancer: The open-label randomized phase III trial JCOG0505. J Clin
Oncol. 33:2129–2135. 2015. View Article : Google Scholar
|
|
30
|
Chen L, Qiu X, Wang R and Xie X: The
efficacy and safety of docetaxel plus thalidomide vs. docetaxel
alone in patients with androgen-independent prostate cancer: A
systematic review. Sci Rep. 4:48182014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li L and Huang XE: Thalidomide combined
with chemotherapy in treating patients with advanced lung cancer.
Asian Pac J Cancer Prev. 17:2583–2585. 2016.PubMed/NCBI
|
|
32
|
Downs LS Jr, Rogers LM, Yokoyama Y and
Ramakrishnan S: Thalidomide and angiostatin inhibit tumor growth in
a murine xenograft model of human cervical cancer. Gynecol Oncol.
98:203–210. 2005. View Article : Google Scholar
|
|
33
|
Mohanty S, Huang J and Basu A: Enhancement
of cisplatin sensitivity of cisplatin-resistant human cervical
carcinoma cells by bryostatin 1. Clin Cancer Res. 11:6730–6737.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hernandez MO, Fulco TO, Pinheiro RO,
Pereira RM, Redner P, Sarno EN, Lopes UG and Sampaio EP:
Thalidomide modulates Mycobacterium leprae-induced NF-κB pathway
and lower cytokine response. Eur J Pharmacol. 670:272–279. 2011.
View Article : Google Scholar
|
|
35
|
Che Y, Li Y, Zheng F, Zou K, Li Z, Chen M,
Hu S, Tian C, Yu W, Guo W, et al: TRIP4 promotes tumor growth and
metastasis and regulates radiosensitivity of cervical cancer by
activating MAPK, PI3K/AKT, and hTERT signaling. Cancer Lett.
452:1–13. 2019. View Article : Google Scholar
|
|
36
|
Yan CM, Zhao YL, Cai HY, Miao GY and Ma W:
Blockage of PTPRJ promotes cell growth and resistance to 5-FU
through activation of JAK1/STAT3 in the cervical carcinoma cell
line C33A. Oncol Rep. 33:1737–1744. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Morgan EL, Chen Z and Waes CV: Regulation
of NFκB signalling by ubiquitination: A potential therapeutic
target in head and neck squamous cell carcinoma? Cancers (Basel).
12:28772020. View Article : Google Scholar
|
|
38
|
Morgan EL and Macdonald A: Autocrine STAT3
activation in HPV positive cervical cancer through a virus-driven
Rac1-NFκB-IL-6 signalling axis. PLoS Pathog. 15:e10078352019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cochicho D, Esteves S, Rito M, Silva F,
Martins L, Montalvão P, Cunha M, Magalhães M, da Costa RMG and
Felix A: PIK3CA gene mutations in HNSCC: Systematic review and
correlations with HPV status and patient survival. Cancers (Basel).
14:12862022. View Article : Google Scholar : PubMed/NCBI
|
